Trinity Biotech PLC (NASDAQ:TRIB – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.71 and traded as high as $0.83. Trinity Biotech shares last traded at $0.82, with a volume of 300,833 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen began coverage on Trinity Biotech in a report on Saturday, May 17th. They set a “sell” rating for the company.
Trinity Biotech Stock Performance
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Read More
- Five stocks we like better than Trinity Biotech
- What Does a Stock Split Mean?
- Analysts Make a Quantum Bet on D-Wave’s Cryogenic Packaging
- P/E Ratio Calculation: How to Assess Stocks
- Traders Turn Bullish on Housing Stocks Again—3 Leading the Way
- Quiet Period Expirations Explained
- Onsemi’s August Pullback Is a Signal to Buy for Tech Investors
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
